Dianthus Therapeutics, Inc. /DE/
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 7 TIMES SQUARE, NEW YORK, NY, 10036
Mailing Address 7 TIMES SQUARE, NEW YORK, NY, 10036
Phone 929-999-4055
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 11, 2026 | View on SEC |
| 10-K Annual financial report | March 9, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
Annual Reports
10-K March 9, 2026
- Lead investigational drug, Claseprubart (C1s inhibitor), is in Phase 2/3 clinical trials for generalized Myasthenia Gravis (gMG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
- Second promising candidate, DNTH212 (oral C3 inhibitor), is in preclinical development with an IND filing expected in late 2024 for human studies.
Insider Trading
STRONG SELL 5 insiders
13 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.